An Open-label, Phase I Study to Assess the Pharmacokinetics of R406 in Subjects With Renal Impairment Compared to Healthy Subjects Following Administration of a Single Dose of Fostamatinib 150 mg.
Phase of Trial: Phase I
Latest Information Update: 27 Oct 2015
At a glance
- Drugs Fostamatinib (Primary)
- Indications Cancer; Rheumatoid arthritis; Type 1 diabetes mellitus
- Focus Pharmacokinetics
- 27 Oct 2015 Results published in the Clinical Therapeutics
- 15 Jun 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
- 15 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.